Rosen Law Firm, a securities litigation firm, has initiated a class action lawsuit against Corcept Therapeutics Incorporated on behalf of investors who purchased the company's common stock between October 31, 2024 and December 30, 2025. The lawsuit alleges that Corcept made materially misleading statements regarding clinical trial data and regulatory approval prospects for its relacorilant drug candidate.
According to the filing, the company's public disclosures failed to adequately represent concerns raised by the U.S. Food and Drug Administration regarding the sufficiency of clinical evidence submitted in support of the drug's New Drug Application. The complaint contends that investors were not properly informed about the regulatory challenges facing the relacorilant program, which may have materially affected their investment decisions.
The firm is urging eligible investors to retain legal counsel before the applicable deadline in the matter. Class action lawsuits of this nature typically seek damages for investors who purchased securities during the alleged period of material misrepresentation.